A Phase 3 interventional study of 9vHPV Vaccine and Dengue Tetravalent Vaccine (TDV) in Dengue Fever, sponsored by Takeda. Completed at 4 sites in Thailand. Open to participants aged 9 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-07.
Sponsored by Takeda · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Dengue by Takeda — 2 open to participants now, 5 under way, 3 of them phase 3. Dengue · Takeda.
Among the 17 studies in Dengue by Takeda, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2021, is one of 9 in phase 3, and was the 11th registered.
283 studies on the registry are indexed under Dengue; 44 are open to participants now.
Browse Dengue studies →2 of the 17 studies in Dengue by Takeda are open now, in 4 countries. Recruiting first, the newest first:
Takeda · Sites in Colombia, Thailand
Ages 6 mo–20 mo · Healthy volunteers
Takeda · Sites in Indonesia, Malaysia, Thailand
Ages 6–12 · Healthy volunteers
By country, each count listing its studies:
Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 9 Years to 14 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 10
First in 2013; this study’s year is marked. 1 started in 2021.
This study's enrollment of 614 is above the median of 132 across 197 interventional studies indexed under Dengue.
Median enrollment 400 across the 15 interventional studies, 36,000 across the 2 observational. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
2 of the studies in Dengue by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579755Phase 3TakedaA Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) | 2027-04-14 |
| NCT06388785TakedaA Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia | 2027-05-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Dengue by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to demonstrate the non-inferiority (NI) of the immune response to 2 doses of 9vHPV vaccine, 1 co-administered with TDV, compared with 2 doses of 9vHPV vaccine administered alone.
The vaccine being tested in this study is called Tetravalent Dengue Vaccine (TDV). The study will assess the immunogenicity and safety on the co-administration of 9vHPV vaccine with TDV in healthy participants aged ≥9 to \<15 years.
The study will enroll approximately 614 healthy volunteers. Participants will be randomly assigned to one of the two treatment groups-
All participants will receive recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) intramuscular (IM) in combination with Dengue Tetravalent Vaccine (TDV) subcutaneous (SC) injection on Day 1 (Month 0 ) followed by 9vHPV on Day 90 (Month 3) and TDV on Day 180 (Month 6) in Group 1. Participants will receive 9vHPV on Day 1 (Month 0) and Day 180 (Month 6) IM in Group 2.
This multi-center trial will be conducted in Thailand. The overall time to participate in this study is 12 months. Participants will make multiple visits to the clinic, after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known or suspected impairment/alteration of immune function, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 0.5 mL 9vHPV intramuscularly (IM) with 0.5 mL TDV subcutaneously (SC) once on Day 1 (Month 0) followed by 0.5 mL TDV SC once on Day 90 (Month 3) and 0.5 mL 9vHPV IM once on Day 180 (Month 6).
Biological: 9vHPV Vaccine · Biological: Dengue Tetravalent Vaccine (TDV)
Participants will receive 0.5 mL 9vHPV vaccine IM once on Day 1 (Month 0) followed by 0.5 mL 9vHPV vaccine IM once on Day 180 (Month 6).
Biological: 9vHPV Vaccine
9vHPV intramuscular injection
TDV subcutaneous injection
Also known as: TAK-003
Geometric Mean Titers (GMTs) for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, 58
GMTs for HPV were measured by immunoglobulin G binding assay (IgGBA) assay. HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58 were the types of HPV analyzed.
Time frame: Day 210 (Month 7)
Percentage of Participants With Seropositivity for HPV Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 as Measured by Immunoglobulin G Binding Assay (IgGBA)
Seropositive for HPV is defined as anti-HPV titers greater or equal to the prespecified cutoffs for any of the 9 HPV serotypes: HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58, measured by IgGBA. The serostatus cut-off is the antibody titer level above the assay's lower limit of quantification that reliably distinguishes sera samples classified by clinical likelihood of HPV infection and positive or negative status by previous versions of IgGBA or equivalent assay. The serostatus cut-offs for the 9 HPV serotypes: HPV-6= 9, HPV-11= 6, HPV-16= 5, HPV-18= 5, HPV-31= 3, HPV-33= 4, HPV-45= 3, HPV-52= 5 and HPV-58= 5. Percentages are rounded off to the nearest decimal point.
Time frame: Day 210 (Month 7)
GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes
GMTs of neutralizing antibodies for each of the 4 dengue serotypes were measured by microneutralization test 50% (MNT50). The four dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only.
Time frame: Day 120 (Month 4)
Percentage of Participants With Seropositivity for Each of the 4 Dengue Serotypes
Seropositivity is defined as a reciprocal neutralizing antibody titer ≥10 for any of the 4 dengue serotypes. The four dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only. Percentages are rounded off to the nearest decimal point.
Time frame: Day 120 (Month 4)
Percentage of Participants With Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes
Seropositivity is defined as a reciprocal neutralizing antibody titer ≥10 for any of the 4 dengue serotypes. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized for categories with at least one participant with event: trivalent (seropositive for 3 dengue serotypes), and tetravalent (seropositive for all 4 dengue serotypes). As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only. Percentages are rounded off to the nearest decimal point.
Time frame: Day 120 (Month 4)
Percentage of Participants With Solicited Local Adverse Events for 7 Days Following Vaccination by Severity
Solicited local adverse events (AEs) (at injection site) were collected by participants using diary cards within 7 days after vaccination and included: Pain \[Grade 0 (no pain), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents daily activity with or without treatment)\]; erythema and swelling \[Grade 0 (\<25 millimeters \[mm\]), 1 (25 - ≤ 50 mm), 2 (\>50 - ≤ 100 mm), 3 (\> 100 mm)\]. Percentages are rounded off to the nearest decimal point. The data for solicited local adverse events after any vaccination are presented. Only those categories with at least 1 participant with event are reported.
Time frame: Up to 7 days (Day of vaccination + 6 subsequent days) after each vaccination
Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 14 Days Following Vaccination by Severity
Solicited systemic AEs were collected by participants using diary cards within 14 days after vaccination and included fever, headache, asthenia, malaise, and myalgia. Severity grades were: Grade 0: none, Grade 1: mild (no interference with daily activity), Grade 2: moderate (interference with daily activity with or without treatment), Grade 3: severe (prevents normal daily activity with or without treatment). Fever is defined as body temperature greater than or equal to 38°C (100.4 degrees Fahrenheit \[°F\]). Only categories with at least one participant with event following any vaccination are reported. Percentages are rounded off to the nearest decimal point. The data for solicited systemic adverse events after any vaccination are presented.
Time frame: Up to 14 days (Day of vaccination + 13 subsequent days) after each vaccination
Percentage of Participants With Any Unsolicited AEs for 28 Days Following Vaccination
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a study vaccine; it does not necessarily have to have a causal relationship with study vaccine administration. Percentages are rounded off to the nearest decimal point. The data for unsolicited adverse events after any vaccination are presented.
Time frame: Up to 28 days (Day of vaccination + 27 subsequent days) after each vaccination
Percentage of Participants With Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence or effect that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important which may require intervention to prevent the items listed above or may expose the participant to danger.
Time frame: From first vaccination (Day 1 [Month 0]) through end of study (Day 360 [Month 12])
Participants took part in the study at 4 investigative sites in Thailand from 15 May 2021 to 19 July 2022.
| Milestone | 9vHPV+TDV | 9vHPV |
|---|---|---|
| Started | 307 | 307 |
| Completed | 302 | 304 |
| Not completed | 5 | 3 |
| Withdrew: Withdrawal of consent | 3 | 3 |
| Withdrew: Met exclusion criteria | 1 | 0 |
| Withdrew: Invalid informed consent form (icf) | 1 | 0 |
GMTs for HPV were measured by immunoglobulin G binding assay (IgGBA) assay. HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58 were the types of HPV analyzed.
| titer | 9vHPV+TDV | 9vHPV |
|---|---|---|
| HPV-6 | 1633.693 (1465.31 to 1821.43) | 1790.986 (1556.08 to 2061.35) |
| HPV-11 | 1342.745 (1225.64 to 1471.04) | 1325.192 (1164.58 to 1507.95) |
| HPV-16 | 7777.694 (6989.76 to 8654.45) | 7822.564 (6701.83 to 9130.71) |
| HPV-18 | 2309.629 (2075.91 to 2569.66) | 2506.309 (2182.67 to 2877.93) |
| HPV-31 | 1690.941 (1529.39 to 1869.55) | 1736.943 (1515.05 to 1991.33) |
| HPV-33 | 1138.716 (1019.66 to 1271.67) | 1179.469 (1033.66 to 1345.84) |
| HPV-45 | 504.033 (453.46 to 560.24) | 584.198 (509.91 to 669.31) |
| HPV-52 | 585.606 (533.44 to 642.87) | 561.007 (492.77 to 638.69) |
| HPV-58 | 1163.600 (1060.23 to 1277.05) | 1284.504 (1130.63 to 1459.32) |
Seropositive for HPV is defined as anti-HPV titers greater or equal to the prespecified cutoffs for any of the 9 HPV serotypes: HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58, measured by IgGBA. The serostatus cut-off is the antibody titer level above the assay's lower limit of quantification that reliably distinguishes sera samples classified by clinical likelihood of HPV infection and positive or negative status by previous versions of IgGBA or equivalent assay. The serostatus cut-offs for the 9 HPV serotypes: HPV-6= 9, HPV-11= 6, HPV-16= 5, HPV-18= 5, HPV-31= 3, HPV-33= 4, HPV-45= 3, HPV-52= 5 and HPV-58= 5. Percentages are rounded off to the nearest decimal point.
| percentage of participants | 9vHPV+TDV | 9vHPV |
|---|---|---|
| HPV-6 | 100.0 (98.5 to 100.0) | 99.1 (96.9 to 99.9) |
| HPV-11 | 100.0 (98.5 to 100.0) | 99.1 (96.9 to 99.9) |
| HPV-16 | 100.0 (98.5 to 100.0) | 99.1 (96.9 to 99.9) |
| HPV-18 | 100.0 (98.5 to 100.0) | 99.1 (96.9 to 99.9) |
| HPV-31 | 100.0 (98.5 to 100.0) | 99.1 (96.9 to 99.9) |
| HPV-33 | 100.0 (98.5 to 100.0) | 99.1 (96.9 to 99.9) |
| HPV-45 | 100.0 (98.5 to 100.0) | 99.1 (96.9 to 99.9) |
| HPV-52 | 100.0 (98.5 to 100.0) | 99.1 (96.9 to 99.9) |
| HPV-58 | 100.0 (98.5 to 100.0) | 99.1 (96.9 to 99.9) |
GMTs of neutralizing antibodies for each of the 4 dengue serotypes were measured by microneutralization test 50% (MNT50). The four dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only.
| titer | 9vHPV+TDV |
|---|---|
| DENV-1 | 719.1 (577.8 to 895.0) |
| DENV-2 | 1691.4 (1411.0 to 2027.4) |
| DENV-3 | 555.4 (462.8 to 666.6) |
| DENV-4 | 494.3 (420.8 to 580.6) |
Seropositivity is defined as a reciprocal neutralizing antibody titer ≥10 for any of the 4 dengue serotypes. The four dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only. Percentages are rounded off to the nearest decimal point.
| percentage of participants | 9vHPV+TDV |
|---|---|
| DENV-1 | 100.0 (98.5 to 100.0) |
| DENV-2 | 99.6 (97.7 to 100.0) |
| DENV-3 | 100.0 (98.5 to 100.0) |
| DENV-4 | 100.0 (98.5 to 100.0) |
Seropositivity is defined as a reciprocal neutralizing antibody titer ≥10 for any of the 4 dengue serotypes. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized for categories with at least one participant with event: trivalent (seropositive for 3 dengue serotypes), and tetravalent (seropositive for all 4 dengue serotypes). As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only. Percentages are rounded off to the nearest decimal point.
| percentage of participants | 9vHPV+TDV |
|---|---|
| Trivalent | 0.4 (0.0 to 2.3) |
| Tetravalent | 99.6 (97.7 to 100.0) |
Solicited local adverse events (AEs) (at injection site) were collected by participants using diary cards within 7 days after vaccination and included: Pain \[Grade 0 (no pain), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents daily activity with or without treatment)\]; erythema and swelling \[Grade 0 (\<25 millimeters \[mm\]), 1 (25 - ≤ 50 mm), 2 (\>50 - ≤ 100 mm), 3 (\> 100 mm)\]. Percentages are rounded off to the nearest decimal point. The data for solicited local adverse events after any vaccination are presented. Only those categories with at least 1 participant with event are reported.
| percentage of participants | 9vHPV+TDV | 9vHPV |
|---|---|---|
| Pain: Mild | 54.1 | 42.8 |
| Pain: Moderate | 9.5 | 6.5 |
| Pain: Severe | 0.7 | 0 |
| Erythema: Mild | 7.5 | 0 |
| Erythema: Moderate | 0.7 | 0 |
| Swelling: Mild | 3.3 | 0 |
Solicited systemic AEs were collected by participants using diary cards within 14 days after vaccination and included fever, headache, asthenia, malaise, and myalgia. Severity grades were: Grade 0: none, Grade 1: mild (no interference with daily activity), Grade 2: moderate (interference with daily activity with or without treatment), Grade 3: severe (prevents normal daily activity with or without treatment). Fever is defined as body temperature greater than or equal to 38°C (100.4 degrees Fahrenheit \[°F\]). Only categories with at least one participant with event following any vaccination are reported. Percentages are rounded off to the nearest decimal point. The data for solicited systemic adverse events after any vaccination are presented.
| percentage of participants | 9vHPV+TDV | 9vHPV |
|---|---|---|
| Headache: Mild | 20.0 | 18.0 |
| Headache: Moderate | 3.0 | 0.7 |
| Headache: Severe | 0.3 | 0 |
| Asthenia: Mild | 16.7 | 12.1 |
| Asthenia: Moderate | 2.0 | 1.0 |
| Asthenia: Severe | 0.3 | 0 |
| Malaise: Mild | 17.7 | 10.5 |
| Malaise: Moderate | 2.0 | 1.3 |
| Malaise: Severe | 0.3 | 0 |
| Myalgia: Mild | 36.1 | 27.8 |
| Myalgia: Moderate | 7.9 | 2.3 |
| Myalgia: Severe | 0.3 | 0.3 |
| Fever: 38.0°C to <38.5°C | 2.0 | 0.3 |
| Fever: 38.5°C to <39.0°C | 0.3 | 0 |
| Fever: 39.0°C to <39.5°C | 0.3 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a study vaccine; it does not necessarily have to have a causal relationship with study vaccine administration. Percentages are rounded off to the nearest decimal point. The data for unsolicited adverse events after any vaccination are presented.
| percentage of participants | 9vHPV+TDV | 9vHPV |
|---|---|---|
| Percentage of Participants With Any Unsolicited AEs for 28 Days Following Vaccination | 8.8 | 2.6 |
An SAE is defined as any untoward medical occurrence or effect that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important which may require intervention to prevent the items listed above or may expose the participant to danger.
| percentage of participants | 9vHPV+TDV | 9vHPV |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) | 10.1 | 7.2 |
Collected over All-cause mortality and serious adverse events: From first vaccination (Day 1 [Month 0]) through end of study (Day 360 [Month 12]); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after each vaccination. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 9vHPV+TDV | 0/307 (0%) | 31/307 (10.1%) | 253/307 (82.4%) |
| 9vHPV | 0/307 (0%) | 22/307 (7.2%) | 223/307 (72.6%) |
| Event | 9vHPV+TDV | 9vHPV |
|---|---|---|
| COVID-19Infections and infestations | 26/307 | 19/307 |
| COVID-19 pneumoniaInfections and infestations | 2/307 | 2/307 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/307 | 0/307 |
| BronchitisInfections and infestations | 1/307 | 0/307 |
| Foreign body in gastrointestinal tractInjury, poisoning and procedural complications | 1/307 | 0/307 |
| GastroenteritisInfections and infestations | 1/307 | 0/307 |
| Limb injuryInjury, poisoning and procedural complications | 0/307 | 1/307 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/307 | 1/307 |
| Event | 9vHPV+TDV | 9vHPV |
|---|---|---|
| PainGeneral disorders | 225/307 | 184/307 |
| MyalgiaMusculoskeletal and connective tissue disorders | 135/307 | 93/307 |
| ErythemaSkin and subcutaneous tissue disorders | 92/307 | 57/307 |
| HeadacheNervous system disorders | 71/307 | 59/307 |
| SwellingGeneral disorders | 64/307 | 52/307 |
| MalaiseGeneral disorders | 62/307 | 36/307 |
| AstheniaGeneral disorders | 58/307 | 40/307 |
| FeverGeneral disorders | 8/307 | 1/307 |
| NasopharyngitisInfections and infestations | 3/307 | 0/307 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 2/307 | 0/307 |
Randomized Set included all randomized participants, regardless of whether any dose of the investigational products (IPs) was received.
| Age, Continuous(years) | 9vHPV+TDV | 9vHPV | Total |
|---|---|---|---|
| Mean | 11.1 ± 1.60 | 11.3 ± 1.59 | 11.2 ± 1.59 |
| Sex: Female, Male(Participants) | 9vHPV+TDV | 9vHPV | Total |
|---|---|---|---|
| Female | 150 | 156 | 306 |
| Male | 157 | 151 | 308 |
| Ethnicity (NIH/OMB)(Participants) | 9vHPV+TDV | 9vHPV | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 307 | 307 | 614 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 9vHPV+TDV | 9vHPV | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 307 | 307 | 614 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 9vHPV+TDV | 9vHPV | Total |
|---|---|---|---|
| Thailand | 307 | 307 | 614 |
| Height(centimeters (cm)) | 9vHPV+TDV | 9vHPV | Total |
|---|---|---|---|
| Mean | 147.68 ± 12.244 | 148.18 ± 11.374 | 147.93 ± 11.809 |
| Weight(kilograms (kg)) | 9vHPV+TDV | 9vHPV | Total |
|---|---|---|---|
| Mean | 44.21 ± 15.913 | 44.37 ± 14.271 | 44.29 ± 15.101 |
| Body Mass Index (BMI)(kilograms per meter square (kg/m^2)) | 9vHPV+TDV | 9vHPV | Total |
|---|---|---|---|
| Mean | 19.78 ± 4.912 | 19.88 ± 4.762 | 19.83 ± 4.834 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2021 to primary completion in Feb 2022, 9 months.
Results were first posted in Feb 2024, 1 year 11 months after primary completion. A results delay was requested in Jan 2023.
Of 21 phase 3 interventional studies under Dengue, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent